Sangamo Therapeutics (SGMOQ) Cash from Financing Activities (2010 - 2025)

Sangamo Therapeutics has reported Cash from Financing Activities for 16 years, with the latest figure at $14.8 million in Q4 2025.

• On a quarterly basis, Cash from Financing Activities rose 111.66% year-over-year to $14.8 million in Q4 2025; TTM through Dec 2025 was $70.7 million, a 149.32% increase from a year earlier, with the FY2025 full-year figure at $70.7 million, up 149.32% from the prior year.
• Cash from Financing Activities was $14.8 million for Q4 2025 at Sangamo Therapeutics, down from $19.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $43.8 million in Q3 2022, with the low at -$1.6 million in Q1 2022.
• Average Cash from Financing Activities over 5 years is $11.6 million, with a median of $8.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities slumped 110.29% in 2022, then surged 9560.1% in 2025.
• Over 5 years, Cash from Financing Activities stood at $2.1 million in 2021, then soared by 824.95% to $19.5 million in 2022, then tumbled by 99.15% to $167000.0 in 2023, then surged by 4086.23% to $7.0 million in 2024, then soared by 111.66% to $14.8 million in 2025.
• The last three Cash from Financing Activities figures came in at $14.8 million (Q4 2025), $19.2 million (Q3 2025), and $28.6 million (Q2 2025), per Business Quant data.